Compare SY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | SLN |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | China | United Kingdom |
| Employees | N/A | 88 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 300.9M |
| IPO Year | 2018 | N/A |
| Metric | SY | SLN |
|---|---|---|
| Price | $1.68 | $10.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.50 | ★ $42.60 |
| AVG Volume (30 Days) | 441.8K | ★ 622.1K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.64 | N/A |
| Revenue Next Year | $30.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $4.19 |
| 52 Week High | $6.28 | $11.06 |
| Indicator | SY | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 63.62 |
| Support Level | $1.28 | $5.87 |
| Resistance Level | $1.79 | $11.06 |
| Average True Range (ATR) | 0.13 | 0.82 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 62.22 | 73.46 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.